UY25936A1 - Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista - Google Patents

Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista

Info

Publication number
UY25936A1
UY25936A1 UY25936A UY25936A UY25936A1 UY 25936 A1 UY25936 A1 UY 25936A1 UY 25936 A UY25936 A UY 25936A UY 25936 A UY25936 A UY 25936A UY 25936 A1 UY25936 A1 UY 25936A1
Authority
UY
Uruguay
Prior art keywords
agonist
alpha
clonidine
opioid
physiologically tolerable
Prior art date
Application number
UY25936A
Other languages
English (en)
Inventor
Johannes Bartholomaeus
Juergen Betzing
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of UY25936A1 publication Critical patent/UY25936A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulaciones medicamentosas retardadas que contienen una combinación de un opioide o una sal fisiológicamente tolerable del mismo, y un alfa-agonista o una sal fisiológicamente tolerable del mismo, conjuntamente con lactosa o fosfato monoácido cálcico, con o sin otros excipientes farmacéuticos, así como su uso en estados álgidos de mediana intensidad hasta agudos severos o crónicos. Los opioides están elegidos del grupo que comprende morfina, hidromorfona, codeína, oxicodona, dihidrocodeína, dextropropoxifen, buprenorfina, levometadona, fentanil, sufentanil, etorfina, pentazocina, tilidina, tramadol, levorfanol, metadona, dihidromorfina, petidina, piritramida o una sal fisiológicamente aceptable de los mismos. El alfa-agonista se selecciona del grupo que comprende clonidina, guanfacina, guanabenz, lofexidina, adrenalina, metildopa, noradrenalina, metoxamina, oximetazolina, xilometazolina, terizolina, medetomidina, dexmedetomidina, agmatina, para-amino-clonidina, xilazina, talipexol, nafazolina, tizanidina o una sal fisiológicamente tolerable de los mismos.
UY25936A 1999-01-18 2000-01-17 Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista UY25936A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901684 1999-01-18

Publications (1)

Publication Number Publication Date
UY25936A1 true UY25936A1 (es) 2001-07-31

Family

ID=7894563

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25936A UY25936A1 (es) 1999-01-18 2000-01-17 Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista

Country Status (15)

Country Link
US (1) US20020044966A1 (es)
EP (1) EP1143936A2 (es)
JP (1) JP2002534458A (es)
AR (1) AR022252A1 (es)
AU (1) AU772886B2 (es)
BR (1) BR0000578A (es)
CA (1) CA2359273A1 (es)
CO (1) CO5160243A1 (es)
HU (2) HU0000139D0 (es)
NO (2) NO20000225D0 (es)
NZ (1) NZ513501A (es)
PE (1) PE20001396A1 (es)
SK (1) SK10012001A3 (es)
UY (1) UY25936A1 (es)
WO (1) WO2000041681A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP1326642A2 (en) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
IL158819A0 (en) * 2001-05-31 2004-05-12 Skyepharma Inc Encapsulation of nanosuspensions in liposomes and microspheres
CA2452871C (en) * 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US7854230B2 (en) * 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
US7485323B2 (en) * 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
JP5726401B2 (ja) * 2005-07-28 2015-06-03 シャイア エルエルシー 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形／組成物
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
EP2155170A2 (en) * 2007-06-08 2010-02-24 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
EP2265259A1 (en) * 2008-04-25 2010-12-29 Cadila Healthcare Limited Rapidly disintegrating oral compositions of tramadol
WO2009158477A1 (en) * 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
JP5536661B2 (ja) * 2008-10-30 2014-07-02 国立大学法人 岡山大学 局所麻酔用組成物
AU2010339882B2 (en) * 2009-12-17 2016-10-27 Cima Labs Inc. Abuse-resistant formulations
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
CA2850964C (en) 2011-10-05 2021-02-02 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
CN105764496B (zh) 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN112494486B (zh) * 2020-12-07 2022-01-21 深圳善康医疗健康产业有限公司 一种用于减轻或消除阿片戒断综合症的药物组合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946848A (en) * 1985-10-29 1990-08-07 Baker Cumins Dermatologicals, Inc. Method of treating pruritus with nalmefene and clonidine
PT99629A (pt) * 1991-11-28 1993-05-31 Antonio Feria Reis Valle Metodo de desintoxicacao de opiaceos
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
DE19749724A1 (de) * 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln

Also Published As

Publication number Publication date
CA2359273A1 (en) 2000-07-20
CO5160243A1 (es) 2002-05-30
HU0000139D0 (en) 2000-03-28
NZ513501A (en) 2003-11-28
EP1143936A2 (de) 2001-10-17
JP2002534458A (ja) 2002-10-15
WO2000041681A2 (de) 2000-07-20
HUP0105043A3 (en) 2005-06-28
PE20001396A1 (es) 2000-12-23
AU772886B2 (en) 2004-05-13
NO20013302L (no) 2001-07-03
BR0000578A (pt) 2001-08-14
HUP0105043A2 (en) 2002-06-29
NO20000225D0 (no) 2000-01-17
US20020044966A1 (en) 2002-04-18
AU2109000A (en) 2000-08-01
NO20013302D0 (no) 2001-07-03
SK10012001A3 (sk) 2002-01-07
AR022252A1 (es) 2002-09-04
WO2000041681A3 (de) 2000-12-07

Similar Documents

Publication Publication Date Title
UY25936A1 (es) Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista
TW200514581A (en) In-situ gelling drug delivery system
BRPI0418228A (pt) forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
BRPI0714712B8 (pt) dispositivo para administração de fármaco
WO2003090726A3 (en) Chewable soft capsule
PE20050146A1 (es) Forma de dosificacion transdermica resistente a la manipulacion
AR076540A1 (es) Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor
US20210196706A1 (en) Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
WO2007061828A3 (en) Pharmaceutical compositions comprising buprenorphine
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
ES2963078T3 (es) Formulaciones de liberación inmediata disuasorias del abuso que comprenden polisacáridos no celulósicos
MXPA04003597A (es) Conjugados polimericos de antagonistas opiaceos.
TR200103302T2 (tr) Diamorfin etkin maddeli farmasötik preparat
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
JP2010189403A5 (es)
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
BRPI0606247A2 (pt) uso de oxicodona para tratamento da dor visceral
NZ612837A (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson’s disease
CL2011000044A1 (es) Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
CY1109031T1 (el) Τριαζασπιρο ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου
TR201002473A2 (tr) Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
WO2012166891A3 (en) Mu-opioid receptor binding compounds
NZ599957A (en) Drug combination with theobromine and its use in therapy
JP2013510842A5 (es)

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20100111